search icon
Join IDSAJOIN IDSA >> Go to MyIDSAGO TO MYIDSA >>
  • Print
  • ShareThis
  • Text Size

IDSA Practice Guidelines

Practice guidelines are systematically developed statements to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances. [Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, 1990]

Attributes of good guidelines include validity, reliability, reproducibility, clinical applicability, clinical flexibility, clarity, multidisciplinary process, review of evidence, and documentation. [Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, 1990]

Keyword Search

...

Search Results

11 results found

Community-Acquired Pneumonia (CAP) in Infants and Children

Status: Current

Evidenced-based guidelines for management of infants and children with community-acquired pneumonia (CAP) were prepared by an expert panel comprising clinicians and investigators representing community pediatrics, public health, and the pediatric

Evidenced-based guidelines for management of infants and children with community-acquired pneumonia (CAP) were prepared by an expert panel comprising clinicians and investigators representing community pediatrics, public health, and the pediatric specialties of critical care, emergency medicine, hospital medicine, infectious diseases, pulmonology, and surgery. These guidelines are intended for use by primary care and subspecialty providers responsible for the management of otherwise healthy infants and children with CAP in both outpatient and inpatient settings. Full text*Every 12 to 18 months following publication, IDSA reviews its guidelines to determine whether an update is required. This guideline was last reviewed and deemed current as of 04/2013.

Combat-Related Infections

Status: Current, Endorsed

Despite advances in resuscitation and surgical management of combat wounds, infection remains a concerning and potentially preventable complication of combat-related injuries. Interventions currently used to prevent these infections have not

Despite advances in resuscitation and surgical management of combat wounds, infection remains a concerning and potentially preventable complication of combat-related injuries. Interventions currently used to prevent these infections have not been either clearly defined or subjected to rigorous clinical trials. Current infection prevention measures and wound management practices are derived from retrospective review of wartime experiences, from civilian trauma data, and from in vitro and animal data. This update to the guidelines published in 2008 incorporates evidence that has become available since 2007. These guidelines focus on care provided within hours to days of injury, chiefly within the combat zone, to those combat-injured patients with open wounds or burns. New in this update are a consolidation of antimicrobial agent recommendations to a backbone of high-dose cefazolin with or without metronidazole for most post injury indications, and recommendations for redosing of antimicrobial agents, for use of negative pressure wound therapy, and for oxygen supplementation in flight.*For information on the timing of an update to this guideline, please contact the AFIDS.

Prevention of Catheter-related Infections

Status: Current, Endorsed

These guidelines have been developed for healthcare personnel who insert intravascular catheters and for persons responsible for surveillance and control of infections in hospital, outpatient, and home healthcare settings. This

These guidelines have been developed for healthcare personnel who insert intravascular catheters and for persons responsible for surveillance and control of infections in hospital, outpatient, and home healthcare settings. This report was prepared by a working group comprising members from professional organizations representing the disciplines of critical care medicine, infectious diseases, healthcare infection control, surgery, anesthesiology, interventional radiology, pulmonary medicine, pediatric medicine, and nursing.Full text*For information on the timing of future updates to this guideline, contact the SCCM.

Neutropenic Patients with Cancer

Status: Current

This document updates and expands the initial Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guideline that was published in 1997 and first updated in 2002. It is intended

This document updates and expands the initial Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guideline that was published in 1997 and first updated in 2002. It is intended as a guide for the use of antimicrobial agents in managing patients with cancer who experience chemotherapy-induced fever and neutropenia.Recent advances in antimicrobial drug development and technology, clinical trial results, and extensive clinical experience have informed the approaches and recommendations herein. Because the previous iteration of this guideline in 2002, we have a developed a clearer definition of which populations of patients with cancer may benefit most from antibiotic, antifungal, and antiviral prophylaxis. Furthermore, categorizing neutropenic patients as being at high risk or low risk for infection according to presenting signs and symptoms, underlying cancer, type of therapy, and medical comorbidities has become essential to the treatment algorithm. Risk stratification is a recommended starting point for managing patients with fever and neutropenia. In addition, earlier detection of invasive fungal infections has led to debate regarding optimal use of empirical or preemptive antifungal therapy, although algorithms are still evolving.What has not changed is the indication for immediate empirical antibiotic therapy. It remains true that all patients who present with fever and neutropenia should be treated swiftly and broadly with antibiotics to treat both gram-positive and gram-negative pathogens.Finally, we note that all Panel members are from institutions in the United States or Canada; thus, these guidelines were developed in the context of North American practices. Some recommendations may not be as applicable outside of North America, in areas where differences in available antibiotics, in the predominant pathogens, and/or in health care–associated economic conditions exist. Regardless of venue, clinical vigilance and immediate treatment are the universal keys to managing neutropenic patients with fever and/or infection.Full text*Every 12 to 18 months following publication, IDSA reviews its guidelines to determine whether an update is required. This guideline was last reviewed and deemed current as of 04/2013.

MRSA

Status: Current

Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are

Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections. Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, and vancomycin treatment failures. Full text*Every 12 to 18 months following publication, IDSA reviews its guidelines to determine whether an update is required. This guideline was last reviewed and deemed current as of 12/2012.

Uncomplicated Cystitis and Pyelonephritis (UTI)

Status: Current

A Panel of International Experts was convened by the Infectious Diseases Society of America (IDSA) in collaboration with the European Society for Microbiology and Infectious Diseases (ESCMID) to update the

A Panel of International Experts was convened by the Infectious Diseases Society of America (IDSA) in collaboration with the European Society for Microbiology and Infectious Diseases (ESCMID) to update the 1999 Uncomplicated Urinary Tract Infection Guidelines by the IDSA. Co-sponsoring organizations include the American Congress of Obstetricians and Gynecologists, American Urological Association, Association of Medical Microbiology and Infectious Diseases–Canada, and the Society for Academic Emergency Medicine. The focus of this work is treatment of women with acute uncomplicated cystitis and pyelonephritis, diagnoses limited in these guidelines to premenopausal, non-pregnant women with no known urological abnormalities or co-morbidities. The issues of in vitro resistance prevalence and the ecological adverse effects of antimicrobial therapy (collateral damage) were considered as important factors in making optimal treatment choices and thus are reflected in the rankings of recommendations.  Full text*Every 12 to 18 months following publication, IDSA reviews its guidelines to determine whether an update is required. This guideline was last reviewed and deemed current as of 07/2013.

IV Catheter Japanese Version

Status: Update in Progress

"血管内カテーテル関連感染症の診断と治療に関する" [ektdesignns_placeholder_ID0ELC]

"血管内カテーテル関連感染症の診断と治療に関する" [ektdesignns_placeholder_ID0ELC]

MRSA - Italian

Status: Current

Linee guida evidence-basedper la gestione deipazienti affetti daStaphylococcus aureus resistente allameticillina (MRSA),le infezionisono state preparateda ungruppo di espertidimalattie infettive Society ofAmerica (IDSA).Le linee guida sonodestinate ad essere utilizzatedaoperatori sanitariche si

Linee guida evidence-basedper la gestione deipazienti affetti daStaphylococcus aureus resistente allameticillina (MRSA),le infezionisono state preparateda ungruppo di espertidimalattie infettive Society ofAmerica (IDSA).Le linee guida sonodestinate ad essere utilizzatedaoperatori sanitariche si occupano dipazienti adultie pediatrici coninfezioni da MRSA.Le linee guidadiscutere lagestionedi una varietà disindromicliniche associatecon la malattia diMRSA, tra cuile infezionicutanee e dei tessutimolli (SSTI),batteriemiaed endocardite, polmonite,infezioniosseeearticolari,e sistema nervoso centrale(SNC)infezioni.Le raccomandazioni sonofornite riguardodosaggiovancomicinae il monitoraggio, la gestionedelle infezionidovute a ceppiMRSAcon ridotta sensibilitàalla vancomicinaefallimenti del trattamentovancomicina.

Directrizes Praticas da Infectious Disease Society

Status: Update in Progress

Estas diretrizes baseadas em evidências para o manejo de infecções por Staphylococcus aureusresistentes à meticilina (MRSA) foram preparadas por um grupo de especialistas da >Infectious Diaseases Society of America (IDSA). As

Estas diretrizes baseadas em evidências para o manejo de infecções por Staphylococcus aureusresistentes à meticilina (MRSA) foram preparadas por um grupo de especialistas da >Infectious Diaseases Society of America (IDSA). As diretrizes destinam-se a profissionais de saúde que atendem a pacientes adultos e crianças com infecções por MRSA. Elas discutem o manejo de várias síndromes clínicas associadas à doença por MRSA, inclusive as infecções de pele e partes moles (IPPM), a bacteremia e a endocardite, a pneumonia, as infecções ósseas e articulares e do sistema nervoso central (SNC). São feitas recomendações quanto à dosagem e monitoramento da vancomicina, ao manejo das infecções por cepas de MRSA com susceptibilidade reduzida à vancomicina e das falhas terapêuticas da vancomicina.

Neutropenic Patients with Cancer- Turkish

Status: Update in Progress

Bu belgegüncellemeleri veilkAmerikaEnfeksiyon HastalıklarıDerneği (IDSA)Ateş ve1997 yılında yayınlananveilkkez2002 yılındagüncellendiNötropeniYönergegenişletir.Kanserli hastalardakemoterapi ile indüklenenateş venötropenideneyimyönetmekantimikrobiyal ajanlarınkullanımı içinbir kılavuz olaraktasarlanmıştır.

Bu belgegüncellemeleri veilkAmerikaEnfeksiyon HastalıklarıDerneği (IDSA)Ateş ve1997 yılında yayınlananveilkkez2002 yılındagüncellendiNötropeniYönergegenişletir.Kanserli hastalardakemoterapi ile indüklenenateş venötropenideneyimyönetmekantimikrobiyal ajanlarınkullanımı içinbir kılavuz olaraktasarlanmıştır.

| HIVMA | Contact Us

© Copyright IDSA 2017 Infectious Diseases Society of America

Full Site Mobile Site